Brazil Pharma IP Threat Board 2026

Your fastest way to understand what will block entry, where brand collisions will hit, and which licensing moves are happening before market visibility — using Brazil’s official RPI as a forward-looking dataset.

Built for global IP, legal, regulatory and business leaders. Strategic intelligence only — not a formal legal opinion.

Data Coverage

• Brazilian RPI issues 2859–2871
• 13,000+ trademark filings analyzed
• Patent families assessed via patent databases
• Software & Technology Transfer contracts included

What you receive (license-ready)

• Executive report (PDF/DOCX) with BI/CI findings, limits & audit-safe methodology
• Visual figures: applicant pressure, heatmaps, collision density, trend views, lag proxies
• Patent database-integrated insert (family-level intelligence for barrier strategies)
• Action map (2026): AI uses + guardrails (explainability, LGPD-first design, human validation)
• Designed to answer executive questions fast: “Where are we exposed?” “What blocks entry?” “What is moving before launch?”

Best-fit outcomes (how buyers use it)

• Market-entry timing: avoid late detection of blocking IP or licensing moves
• Brand clearance at scale: identify collision zones and class drift before filing
• FTO pre-screening: prioritize barriers (delivery/formulation/process) before deep-dive counsel spend
• Digital health readiness: align software IP with LGPD + health regulation exposure
• Negotiation leverage: use TT signals as early indicators for partnership/litigation posture

RPI → early signals (not registry)

We treat official publications as competitive movement data — helping you act before disputes become visible.

🔥 What this chart signals (RPI 2861–2870)

This is a Brazil-market activity pressure map — showing who is generating the strongest IP + regulatory footprint signals inside Brazil.

See player-by-player executive interpretation

Johnson & Johnson / Janssen (≈ 480)
Absolute lead. Continuous filing + defense posture across multiple asset types.

Roche / Genentech (≈ 320)
Broad pipeline + deep portfolio maintenance. High collision probability.

Eli Lilly (≈ 125)
Clear strategic rise. Expect increasing pressure in Class 5 and device-related protections.

GSK / Bayer / Regeneron / Takeda / Novartis / MSD
Selective but decisive defense posture — where many disputes occur.

Pfizer / Amgen
Lower visible signals in this window, but high-impact opponents when conflicts arise.

Executive summary: Brazil is becoming a high-pressure IP arena; leaders dominate and accelerators tighten competition windows.

Licensing options (built to sell internally)

Choose based on number of users, redistribution needs, and whether you want recurring monitoring.

Pricing varies by scope and licensing rights. This product is strategic intelligence and risk awareness only.

Request Pricing + Executive Preview

Submit your request and we’ll send pricing + a 1-page executive preview extracted from the Threat Board.

Marcus Julius Zanon • IP Lawyer & Compliance Officer — Brazil/LATAM • Founder, AI-driven IP & Regulatory Intelligence Practice
Website: www.mjzanon.com • Email: [email protected] • WhatsApp: +55 41 99137-1456 • WeChat: MJZANON-BRAZIL
Disclaimer: Strategic intelligence only; not legal advice and not a formal legal opinion. Insights derived from public sources including INPI/RPI and patent intelligence platforms.